Navigation Links
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Date:11/18/2009

t attacks who are at increased risk of suffering future cardiovascular events."

"The Guidelines Committee classified prasugrel, marketed in the United States as Effient, with a Class I rating," said Rogelio Braceras, M.D., senior medical director for Daiichi Sankyo, Inc. "Based on the latest clinical studies and scientific evidence, these guidelines provide clear recommendations for how Effient should be incorporated into medical practice to help reduce risk of cardiovascular events such as heart attacks and blood clots forming around stents."

About Effient

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. Effient helps keep blood platelets from clumping together and developing a blockage in an artery. Effient is approved by the U.S. Food and Drug Administration for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS) who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open.

Important Safety Information about Effient

Antiplatelet medicines, including Effient, can increase the risk of bleeding. If patients have unexplained or excessive bleeding while on Effient, they should contact their doctor right away as some bleeding can be serious, and sometimes may lead to death. Patients should not take Effient if they have a stomach ulcer or other conditions that cause bleeding or if they have a history of stroke or "mini-stroke" (transient ischemic attack or TIA).

If patients are 75 or older, or if they weigh less than 132 pound
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
2. OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy
3. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
4. Symmetry Medical Updates Full Year 2009 Financial Guidance
5. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
6. CVS Caremark Announces Updates to Flu Vaccine Program
7. NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate
8. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
9. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
10. CuraGen Updates CR011-vcMMAE Data at ASCO
11. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... and SPARTANBURG, South Carolina , ... Research Network and Molecular Health have announced a collaboration ... diagnostic decision support to the majority of cancer patients ... Network will collaborate with Molecular Health to harness the ... identify cohorts from hundreds of thousands of patients to ...
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies Ltd. ... medical technologies company, is delighted to announce its ... 31, 2015, which includes revenue for three months ... of $264,340. Revenue from advanced wound care product sales ... 2015 increased 24% to $1,742,672 compared to $1,400,065 ...
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
Breaking Medicine Technology:New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
(Date:5/30/2015)... One of the pervasive problems plaguing the ... available. Often, the ruralness of a location can severely ... areas feeling the crunch of a strained healthcare system, ... paying high premiums and copays, Online USA Doctors ... via the power of the internet. , ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 ProIntro Magnify contains ... designs and animations. Instantly add an elegant opening title to ... from a range of clean design layouts. ProIntro Magnify is ... Magnify is extremely easy to use. Simply drag a preset ... the on-screen-controls and parameters in the Inspector window then watch ...
(Date:5/30/2015)... Nicole Blodgett, Vice President of ... (DIA) designation to further her expertise in the ... for insurance advisors, health care professionals, and financial ... expertise associated with the risk and the cost ... only the latest accomplishment in Nicole's journey with ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... San Francisco, CA (PRWEB) May 30, 2015 ... San Francisco, California, is proud to announce their June ... a featured apartment community in San Francisco, Key Housing ... find quality housing in what is one of the ... Francisco is a plum posting, and understandably anyone who ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3
... Reinberg HealthDay Reporter , THURSDAY, Nov. 17 ... vision problems, a new U.S. government report shows. ... dropped from 26 percent to 18.6 percent, researchers from ... "Our findings are consistent with other findings," said lead ...
... circulating in the blood might be possible with the ... polymers, which could efficiently sift and capture the diseased ... Illinois at Chicago. Dendrimers have been used to ... but in the new study they were employed to ...
... 17 (HealthDay News) -- Children with bipolar disorder and ... time looking at the eyes when trying to identify ... researchers say. This new study finding may help ... dysregulation have difficulty determining other people,s emotional expressions, said ...
... low hemoglobin levels, increased systolic blood pressure, and male gender ... (SCIs), or silent strokes, in children with sickle cell anemia ... published online today in Blood , ... (ASH). Silent strokes are the most common form of ...
... , THURSDAY, Nov. 17 (HealthDay News) -- Most ... according to a new study that challenges previous research ... peer pressure. People with an antisocial personality are ... other people,s problems. Because of this, they may be ...
... antibiotic-resistant infections increasingly common, and a dangerous lack of ... more important than ever to use existing antibiotics appropriately. ... consumers, health care providers, and policymakers about when antibiotics ... do more harm than good, and the tremendous need ...
Cached Medicine News:Health News:Fewer Diabetic Vision Problems Reported: CDC 2Health News:Fewer Diabetic Vision Problems Reported: CDC 3Health News:Molecules on branched-polymer surfaces can capture rare tumor cells in blood 2Health News:Bipolar Kids May Focus on Different Facial Features 2Health News:Study identifies 'silent' stroke risk factors for children with sickle cell anemia 2Health News:Preserving lifesaving antibiotics today and for the future 2
...
Designed to minimize emblolic debris in SVGs and carotids...
... the ability of interventional cardiologists and ... disease, and provides non-interventional cardiologists with ... treatment of patients who have become ... provides a noninvasive, atraumatic treatment for ...
... dual lumen titanium model ... mm inner diameter catheter ... lumen catheters offer larger ... maximum catheter strength. ,Dual ...
Medicine Products: